

# LCBPT - Laboratoire de chimie et biochimie pharmacologiques et toxicologiques

Rapport Hcéres

#### ▶ To cite this version:

Rapport d'évaluation d'une entité de recherche. LCBPT - Laboratoire de chimie et biochimie pharmacologiques et toxicologiques. 2018, Université Paris Descartes, Centre national de la recherche scientifique - CNRS. hceres-02031908

# HAL Id: hceres-02031908 https://hal-hceres.archives-ouvertes.fr/hceres-02031908

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Research evaluation



Department of chemistry and biochemistry (LCBPT)

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Paris Descartes Centre national de la recherche scientifique -CNRS

**EVALUATION CAMPAIGN 2017-2018**GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the experts committee<sup>2</sup>:

Alan Harvey, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>&</sup>lt;sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

<sup>&</sup>lt;sup>2</sup> The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).



This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

# **UNIT PRESENTATION**

**Unit name:** Department of chemistry and biochemistry

Unit acronym: LCBPT

Requested label: UMR

Application type: Renewal

Current number: 8601

Head of the unit

(2017-2018): Ms Marie-Agnès SARI

Project leader

(2019-2023): Mr Laurent Micouin

**Number of teams:** Currently 10 teams and 4 in the project

# **COMMITTEE MEMBERS**

Chair: Mr Alan Harvey, Strathclyde University, United Kingdom

**Experts:** Ms Claire Beauvineau, Institut Curie

Mr Jean-Claude Beloeil, CNRS

Ms Évelyne BENOIT, CNRS

Ms Johanna Chluba, université de Bourgogne (representative of CNU)

Mr Michal Hocek, Academy of Sciences of the Czech Republic, Czech

Republic

Mr Pierre-Yves Renard, université de Rouen (representative of CoNRS)

Mr Gerard Roelfes, Faculty of Science and Engineering, The Netherlands

**HCERES** scientific officer:

Mr Georges Massiot

Representatives of supervising institutions and bodies:

Mr Erick Dufourc, INC CNRS

Mr Stephano Marullo, université Paris Descartes



### INTRODUCTION

#### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The Laboratory of Chemistry and Biochemistry Pharmacological and Toxicological (LCBPT) was created in 1984. It is located in the university of Paris Descartes at the "Centre Universitaire des Saints Pères" (CUSP), Faculty of Biomedical Sciences, 45 rue des Saints Pères, 75006 Paris, where it extends over 2 360 m² (first floor: 1 750 m², second floor: 610 m²). The LCBPT was directed by Mr Daniel Mansuy until 2006, then by Ms Isabelle ARTAUD from 2006 to 2014, then by Ms Francine ACHER from 2014 until February 2016,

#### MANAGEMENT TEAM

Since February 2016, the unit is directed by Ms Marie-Agnes SARI (Paris Descartes), with Mr Laurent Micouin as deputy director.

#### **HCERES NOMENCLATURE**

ST4: chemistry.

#### **SCIENTIFIC DOMAIN**

The unit conducts research in chemistry that interfaces with life sciences. Topics include the design and synthesis of chemical probes for use in studies on biochemical and molecular processes, and medicinal chemistry directed at finding leads to new medicines in several therapeutic areas including inflammation, infections and cancer.

#### **UNIT WORKFORCE**

Unit workforce	Number 30/06/2017	Number 01/01/2019	
Permanent staff			
Full professors and similar positions	6	7	
Assistant professors and similar positions	13	13	
Full time research directors (Directeurs de recherche) and similar positions	7	7	
Full time research associates (Chargés de recherche) and similar positions	7	7	
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	0	
High school teachers	0	0	
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	17	16	
TOTAL permanent staff	50	50	
Non-permanent staff			
Non-permanent professors and associate professors, including emeritus	2		



Non-permanent full time scientists, including emeritus, post-docs	2		
Non-permanent supporting personnel	5		
PhD Students	21		
TOTAL non-permanent staff	30		
TOTAL unit	80		

# **GLOBAL ASSESSMENT OF THE UNIT**

The LCBPT conducts chemical research of relevance to the life sciences: synthesis of heterocyclic compounds, RNA analogues, organometallic chemistry and supramolecular chemistry. The unit's research extends into drug metabolism, drug delivery, and drug design directed at therapeutic targets relevant to infectious and immune diseases, cancer, and some neurological disorders. The unit has ten research teams, each of which has a very strong output of papers in appropriate journals, with some excellent articles in very high impact journals. The current team structure implies that too many topics are being covered by too few staff to achieve a truly competitive international position, and the unit will merge the actual teams into four teams with a more focused portfolio of projects that can benefit from the complementary expertise of the unit's scientists, engineers and technicians. By defining explicit goals for each of the new teams, focusing on important topics where the teams can expect to have high scientific and/or societal impact, and making use of existing and new national and international collaborations, the unit can expect to enhance its ability to engage with industry, secure more national and international funding, and create an even stronger scientific output in the next five years.

The evaluation reports of Hceres are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions **Evaluation of research Evaluation of doctoral schools Evaluation of programmes** International evaluation and accreditation





